On September 2, 2026, Valencia-based molecular diagnostics company iPremom announced a €15 million seed round led by Amadeus Capital Partners through the Amadeus APEX Technology Fund, with participation from Barcelona's Asabys Partners and APEX Ventures. The money funds clinical validation studies, commercial rollout of the company's MaiRa platform, and regulatory approval work in both the EU and the US.

Why It Matters

Preeclampsia is where several 2026 funding threads are converging. In late August the Gates Foundation committed up to $35M to Flagship's ProFound Therapeutics to hunt preeclampsia protein drug targets with AI — a therapeutics play. iPremom is the diagnostics half of the same thesis: you cannot deploy an early intervention if you cannot identify who needs it in the first trimester. For investors, the interesting structural feature is the asset itself. A cfRNA platform trained on 26,000 samples is not a single test but a signal-detection engine; iPremom says the same dataset is already surfacing molecular markers for a broader set of complications it plans to add over time. That converts a one-indication diagnostic into a platform with sequential label expansion — a familiar shape to biotech investors and a much rarer one in femtech, where single-product companies have historically struggled to justify follow-on rounds. The gating factors are the usual ones: validation studies must replicate outside the PREMOM cohort, EU and US regulatory clearance are unbudgeted in time, and a first-trimester risk score is only clinically valuable if it comes with something a clinician can actually do about it.

MaiRa is a maternal blood test that reads cell-free RNA (cfRNA) signals to estimate the risk of pregnancy complications — preeclampsia foremost — from the first trimester, months before symptoms present. The scientific basis is more than a decade of work by co-founders Professor Carlos Simón (chairman) and Dr. Tamara Garrido (chief scientific officer). Their case for preeclampsia specifically rests on decidualisation resistance: when the uterine lining fails to develop as expected, it leaves a detectable cfRNA signature in maternal blood as early as 9 to 14 weeks. The platform was trained on more than 26,000 samples linked to 10,000 pregnancies from PREMOM, described by the company as one of Spain's largest prospective clinical studies. CEO Guillermo Ferrando Huertas leads commercialization; the test is already available in Spain through iPremom's own laboratory.

The scale of the problem is the pitch. Amadeus cited WHO/UN figures of roughly 260,000 maternal deaths annually, nearly 2 million stillbirths at 28 weeks or later, and 2.3 million neonatal deaths in the first month of life. Preeclampsia alone affects an estimated 5–8% of pregnancies globally. The structural failure iPremom is attacking is timing: existing diagnostic tools generally identify risk only once complications have begun developing, which leaves clinicians managing rather than preventing. "Pregnancy complications have been under-diagnosed and under-treated for generations, because the field was looking in the wrong place at the wrong time," Simón said. "Our ambition is not just to build a better preeclampsia test, it is to give every pregnant woman a comprehensive, early molecular picture of her pregnancy."

The investor logic has a track record attached. Amadeus partner Pierre Socha noted the firm had previously backed Simón at Igenomix, the IVF genetics company — "iPremom is poised to do the same for prenatal care, an even larger market opportunity." Notably, the round is structured as a seed despite the €15M size and the decade of underlying research, which fits the pattern flagged in SVB data reported in August 2026: women's health seed rounds are now expected to clear bars that Series A once carried.

Sources

Update — 2026-09-03

Initial entry — story first created.